Saturday 17 October 2026
Export HIND’s income statement to Excel — free account
Vyome Holdings, Inc.
HIND Healthcare Biotechnology
In the quarter to June 2026, revenue fell 46.0%, EPS grew 100.0% and free cash flow fell 195.0%, each against the same quarter a year earlier.
1.87
0.04
−2.09%
Follow HIND
Vyome Holdings, Inc. (HIND) P/E ratio
As of 16 October 2026, Vyome Holdings, Inc. (HIND) trades at a P/E ratio of 0.0×. Over the past ten years it has ranged from 0.0× (March 2026) to 0.4× (July 2024); the current reading is higher than 90% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | (50.00%) |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 41 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.4×
Ten-year median
0.0×
Current reading's percentile
90
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ICU SeaStar Medical Holding Corporation compare | n/m |
| CTXR Citius Pharmaceuticals, Inc. compare | n/m |
| RVLP RVL Pharmaceuticals PLC compare | n/m |
| LPCN Lipocine Inc. compare | n/m |
| ALLR Allarity Therapeutics, Inc. compare | n/m |
| KTTA Pasithea Therapeutics Corp. compare | n/m |
| BCDA BioCardia, Inc. compare | n/m |
| CLVSQ Clovis Oncology, Inc. compare | n/m |
| HIND Vyome Holdings, Inc. | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)